Mirum Pharmaceuticals, Inc.
NASDAQ:MIRMBiotechnology
+$3.89 today
- Market cap
- $6.04B
- Beta
- 0.51
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$13.57
Volume 0.50M
Average 0.95M
MIRM Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Mirum Pharmaceuticals, Inc.NASDAQ: MIRM
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $6.94M rose 14.5% year over year, ahead of the +7.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +95.6% a year.
Context
- Depreciation & amortization amounted to 4.7% of revenue in FY2025, down 2.4 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +14.5% holds above the trailing-twelve-month pace of +7.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 24.24M USD
- Year-over-year change
- +2.6%
- 4-year CAGR
- +123.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.24M | +2.6% |
| FY2024 | 2024-12-31 | 23.63M | +118.2% |
| FY2023 | 2023-12-31 | 10.83M | +234.4% |
| FY2022 | 2022-12-31 | 3.24M | +232.1% |
| FY2021 | 2021-12-31 | 975K | — |
Depreciation & Amortization vs competitors
How MIRM compares with its peers on the latest reported figures
- MIRM's LTM Jun 2026 depreciation & amortization of $25.95M is the 3rd highest of the 8 companies compared; the peer median is $4.93M.
- Its year-over-year change of +7.1% is the 2nd highest of 8, against a peer median of -5.7%.
- Depreciation & amortization amounts to 4.2% of revenue for MIRM, versus a peer median of 7.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $47.58M | -13.0% | +43.1% | 7.3% | |
| LTM Mar 2026 | $34.01M | -4.7% | +24.3% | 5.1% | |
| LTM Jun 2026 | $25.95M | +7.1% | +95.6% | 4.2% | |
| LTM Mar 2026 | $5.26M | -5.7% | -15.4% | 8.0% | |
| LTM Mar 2026 | $4.93M | +55.9% | +19.6% | 7.1% | |
| LTM Mar 2026 | $2.88M | -16.2% | +25.6% | 6.4% | |
| LTM Jun 2026 | $1.52M | +7.1% | +47.7% | 0.1% | |
| LTM Mar 2026 | $106K | -33.8% | -39.0% | 294.4% | |
| Peer median (excluding MIRM) | $4.93M | -5.7% | +24.3% | 7.1% | |
Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 19.14M | 77.06M | 186.37M | 336.89M | 521.31M |
| Cost of Revenue | 1.9M | 12.37M | 47.04M | 81.64M | 100.58M |
| Gross Profit | 17.24M | 64.69M | 139.34M | 255.25M | 420.73M |
| Gross Margin | 90.1% | 83.9% | 74.8% | 75.8% | 80.7% |
| Research & Development | 131.43M | 106.84M | 102.61M | 140.63M | 186.18M |
| Selling, General & Admin | 59.22M | 89.07M | 145.88M | 202.22M | 257.03M |
| Operating Expenses | 190.65M | 195.91M | 248.49M | 342.85M | 443.21M |
| Depreciation & Amortization | 975K | 3.24M | 10.83M | 23.63M | 24.24M |
| EBITDA | (65.39M) | (122.85M) | (136.49M) | (48.97M) | 17.21M |
| EBITDA Margin | -341.7% | -159.4% | -73.2% | -14.5% | 3.3% |
| Operating Income | (173.41M) | (131.22M) | (109.15M) | (87.61M) | (22.14M) |
| Operating Margin | -906.1% | -170.3% | -58.6% | -26.0% | -4.2% |
| Interest Income | 366K | 3.86M | 13.74M | 13.79M | 12.73M |
| Interest Expense | 17.59M | 15.98M | 15.11M | 14.31M | 14.39M |
| Other Income / Expenses | 89.46M | (10.85M) | (53.27M) | 694K | 709K |
| Income Before Tax | (83.95M) | (142.07M) | (162.42M) | (86.91M) | (21.43M) |
| Pre-Tax Margin | -438.7% | -184.4% | -87.1% | -25.8% | -4.1% |
| Income Tax Expense | 37K | (6.41M) | 991K | 1.03M | 1.94M |
| Net Income | (83.99M) | (135.67M) | (163.42M) | (87.94M) | (23.36M) |
| Net Margin | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% |
| EPS (Basic) | (2.77) | (4.01) | (4.00) | (1.85) | (0.47) |
| EPS (Diluted) | (2.77) | (4.02) | (4.00) | (1.85) | (0.47) |
| Weighted Avg Shares | 30.32M | 33.84M | 40.89M | 47.52M | 50.2M |
| Weighted Avg Shares (Diluted) | 30.32M | 33.98M | 40.89M | 47.52M | 50.2M |
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
Intrinsic Alpha fair value
Locked
Current Price
$92.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.